The breakout on NNVC is officially here, and it's backed by a massive global health catalyst! 🚀 The company just announced that its revolutionary oral antiviral candidate, NV-387, is ready to ship to combat the expanding Ebola outbreak in the DRC. Because it's an oral gummy that is completely stable at room temperature, it destroys the logistical nightmare of ultra-cold vaccine shipping. The market is just starting to price in this emergency pipeline deployment. Volume is roaring—get in before it breaks past $2.00! 📈💥 #NNVC #BioTech #Bullish
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
